Scholarlink

Purpose <p>This preliminary study evaluated effect sizes of differences in circulating cell-free DNA (cfDNA) levels in blood and urine between older adults with and without sarcopenia.</p> Methods <p>This was a subanalysis of the 2021 Itabashi Longitudinal Study on Aging. Twenty-four participants were selected conveniently and classified using the Asian Working Group for Sarcopenia (AWGS) 2019 criteria (sarcopenia, <i>N</i> = 12; non-sarcopenia,</p> <p><i>N</i> = 10). Plasma and urinary cfDNA were quantified by real-time quantitative polymerase chain reaction (qPCR).</p> Results <p>cfDNA measures showed substantial inter-individual variability, and no clear between-group differences were observed. Plasma cfDNA demonstrated a moderate positive correlation with skeletal muscle mass index (<i>r</i> = 0.43, <i>p</i> = 0.03), but the clinical relevance remains uncertain given the small sample size.</p> Conclusions <p>Larger, well-powered longitudinal studies are needed to clarify whether cfDNA, including mitochondrial and nuclear components, can serve as a biomarker of muscle health and sarcopenia risk in older adults.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Blood and urine cell-free circulating DNA in older adults with sarcopenia: a hypothesis-generating study

  • 期刊论文

  • 发表日期：

    2026年3月20日

查看全文
  • Yasuko Yoshida,
  • Takashi Shida,
  • Masato Yonamine,
  • Yosuke Osuka,
  • Kazuhiro Takekoshi,
  • Hiroyuki Sasai

摘要

Purpose

This preliminary study evaluated effect sizes of differences in circulating cell-free DNA (cfDNA) levels in blood and urine between older adults with and without sarcopenia.

Methods

This was a subanalysis of the 2021 Itabashi Longitudinal Study on Aging. Twenty-four participants were selected conveniently and classified using the Asian Working Group for Sarcopenia (AWGS) 2019 criteria (sarcopenia, N = 12; non-sarcopenia,

N = 10). Plasma and urinary cfDNA were quantified by real-time quantitative polymerase chain reaction (qPCR).

Results

cfDNA measures showed substantial inter-individual variability, and no clear between-group differences were observed. Plasma cfDNA demonstrated a moderate positive correlation with skeletal muscle mass index (r = 0.43, p = 0.03), but the clinical relevance remains uncertain given the small sample size.

Conclusions

Larger, well-powered longitudinal studies are needed to clarify whether cfDNA, including mitochondrial and nuclear components, can serve as a biomarker of muscle health and sarcopenia risk in older adults.